VP, Medical Affairs – Hematology-Oncology

Key Responsibilities

• Lead and scale the Medical Affairs function to support the progression of Nurix’s hematology-oncology programs into late-stage clinical development and future commercial readiness.
• Own the overall Medical Affairs strategy for the hematology-oncology portfolio, ensuring alignment with development plans, portfolio priorities, and corporate objectives.
• Lead development of the scientific platform and differentiated medical narrative for Nurix hematology-oncology programs within rapidly evolving treatment landscapes.
• Partner closely with Clinical Development to shape late-stage medical strategy, including data generation priorities, scientific narrative, external engagement plans, and lifecycle opportunities.
• Develop and execute integrated medical plans across field medical, scientific communications, publications, medical education, medical information, insight gathering, and evidence generation.
• Expand and lead a high-performing MSL organization focused on credible scientific exchange, compliant insight capture, and strong engagement with key external experts, investigators, and treatment centers.
• Lead external engagement in hematologic malignancies, including advisory boards, investigator relationships, disease-area thought leader engagement, and interactions with cooperative groups and broader scientific communities.
• Serve as a senior medical representative of the company with external experts, investigators, and scientific leaders, helping establish Nurix as a credible scientific leader in hematologic malignancies and targeted protein degradation.
• Direct publication and scientific communication strategy for key clinical data, congress presentations, medical content, symposia, and educational initiatives.
• Lead integrated evidence generation strategies spanning registrational support, post-marketing evidence development, real-world evidence, health economics and outcomes research, treatment sequencing, and product differentiation opportunities.
• Partner with Commercial and Market Access to ensure medical strategy informs launch readiness, access planning, medical strategy development, training initiatives, and broader commercialization strategy.
• Monitor the external hematology-oncology landscape, including standard-of-care evolution, competitor data, treatment guidelines, and emerging scientific trends, and translate insights into actionable medical strategy.
• Ensure all Medical Affairs activities are conducted in compliance with applicable legal, regulatory, and company standards.
• Provide medical and scientific leadership to executive governance discussions related to portfolio prioritization, lifecycle strategy, label expansion opportunities, external partnerships, and commercialization readiness.
• Support global Medical Affairs planning and coordination, including scientific congress strategy, evidence generation activities, and external engagement initiatives across key regions.

Qualifications

• MD, PhD, DO, or PharmD required; oncology/hematology experience 15+ years of biopharmaceutical Medical Affairs experience with significant leadership responsibility, including direct accountability for launch and post-approval.
• Demonstrated leadership experience supporting late-stage development and commercialization of hematology-oncology therapies, including launch planning, scientific positioning, and post-approval medical strategy.
• Demonstrated expertise in evidence generation (Phase 3b/4, RWE, HEOR), scientific communications, MSL leadership, and cross-functional launch planning.
• Strong understanding of global and US regulatory, compliance, and payer environments related to medical activities and drug promotion.
• Experience in highly innovative therapeutic platforms, first-in-class mechanisms, or rapidly evolving treatment landscapes strongly preferred.
• Excellent leadership, communication, and collaboration skills, with the ability to operate strategically while remaining hands-on in a fast-moving pre-commercial and launch environment.
• Demonstrated ability to build and scale high-performing Medical Affairs organizations in emerging biotechnology or growth-stage commercial settings preferred.